Advaxis Inc. (NASDAQ:ADXS) continues to move higher in the pre-market session on Thursday.
As of 9:03, ADXS stock is trading higher by 4.55% to $0.60 in the pre-market session with more than 3.61 million shares have traded hands.
ADXS Announced News Late Wednesday
Advaxis Presents Updated Clinical Data from Ongoing Phase 1/2 Trial of ADXS-503 in NSCLC at the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting
- ADXS announced updated data from the Company’s ongoing Phase 1/2 study evaluating ADXS-503 in combination with KEYTRUDA® which will be presented as a poster at the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting.
- ADXS-503 is the first drug construct from the ADXS-HOT off-the-shelf, cancer-type specific, immunotherapy program which leverages Advaxis’ proprietary Lm technology platform to target hotspot mutations that commonly occur in specific cancer types as well as other proprietary, tumor-associated antigens.
“These early results, which include a disease control rate of 44% in the first 9 evaluable patients treated with ADXS-503 as an add on therapy at progression with pembrolizumab, are particularly encouraging given the durable nature of disease control in 3 patients,” said Suresh Ramalingam, M.D., Roberto C. Goizueta Chair for Cancer Research, Director, Division of Medical Oncology and Deputy Director of the Winship Cancer Institute at Emory University School of Medicine.
|SHARES OUTSTANDING||137.96 M|
|SHARE FLOAT (%)||133.29 M (96.62%)|
|% HELD BY INSTITUTIONS||7.51|
Recent Stock Performance
|+/- EMA(20)||0.48 (+20.83%)|
|+/- SMA(50)||0.61 (-4.92%)|
|+/- SMA(200)||0.55 (+5.45%)|
|CCI20||247.7065||OverBought||Chaikin Money Flow||-0.5488||Sell|
|MACD||-0.0454||Sell||Money Flow Index||85.1316||OverBought|
|STOCH (14,3)||53.1942||Buy||STOCH RSI||1.0000||OverBought|